SLS-005 did not significantly slow amyotrophic lateral sclerosis (ALS) progression compared with a placebo in the HEALEY platform…
Articles by Lindsey Shapiro, PhD
Brain Trust Bio (BTB) has been cleared to launch Phase 1 clinical trials in Australia to test the efficacy…
A biomarker test that identifies abnormal protein fragments called cryptic peptides may help detect amyotrophic lateral sclerosis (ALS) and…
When investigational amyotrophic lateral sclerosis (ALS) therapy CNM-Au8 reaches the bloodstream, it attracts a layer of proteins called a…
Treatment with CNM-Au8 was shown to significantly prolong survival — relative to the natural history of the disease —…
Denali Therapeutics’ SAR443820 (DNL788) treatment candidate — now in late-stage clinical testing for amyotrophic lateral sclerosis (ALS), per the…
FundaMental Pharma’s investigational molecule FP802 reduced neurological disability, protected nerve cells, and prolonged survival in a…
Mutations in the C9ORF72 gene may lead to amyotrophic lateral sclerosis (ALS) and the related disorder…
On the heels of promising HEALEY-ALS Phase 2 trial data, Prilenia Therapeutics plans to launch a pivotal Phase 3…
Blocking certain inflammatory signaling pathways may be one way to reverse nerve cell alterations that drive the symptoms of…